Skip to content

Pulse Biosciences

US · PLSE #2388 by market cap Listed 2016
45.55 +1.14 +2.57%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 43.92 -1.10%
After-hours 45.50 -0.11%
58.1724.2845.552026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on PLSE?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +127.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 4.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Gross margin -54.0% Better than 1%
Operating margin -21,982.6% Better than 0%
Net margin -20,794.6% Better than 0%
Return on equity -74.4% Better than 6%
Return on invested capital -72.7% Better than 4%
Momentum A

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -9.7% Better than 51%
6-month return 75.9% Better than 98%
12-month return (ex latest month) 307.5% Better than 100%
Distance below 52-week high 22.7% Better than 55%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 10.5x Better than 94%
Debt to assets 8.0% Better than 73%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 46.4% Better than 64%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.69%
1M -10.41%
3M -4.81%
6M +74.59%
YTD +231.76%
1Y +259.79%
3Y +627.64%
5Y +113.75%

Key statistics

Price & volume

Prev close
44.41
Open
44.00
Day range
43.72 - 46.06
Avg price
45.42
Volume
466.85K
Turnover
21.20M
Amplitude
5.27%
52-week range
12.95 - 58.94

Valuation

P/E
-42.18
P/E (TTM)
-37.64
P/B
18.25
EPS
-1.08
Net profit
-79.43M
Net assets
183.58M

Share structure

Market cap
3.35B
Float cap
1.04B
Shares out
73.55M
Float shares
22.88M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-05-18
52-week range 71% of range
12.95 58.94

22.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-3.61M net over the window

Short interest

Shares short
2.90M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Pulse Biosciences (PLSE)?

Pulse Biosciences last traded at 45.55. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Pulse Biosciences's market cap?

About 3.35B.

What is the P/E ratio of Pulse Biosciences?

The trailing twelve-month P/E is -37.64. The Valuation tab shows it against the stock's own five-year range.

Does Pulse Biosciences pay a dividend?

Pulse Biosciences does not currently pay a regular dividend.

Is Pulse Biosciences a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 66.67, which implies 46.4% upside from the current price. This is not investment advice.

What is Pulse Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Pulse Biosciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Pulse Biosciences discussion 0 comments

Add a comment